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Pancreatic and Transplant Surgery, University of Alberta, Edmonton, CanadaIn the treatment of hepatocellular carcinomas, therapies such as Introduction
trans-arterial chemo-embolisation, trans-arterial radioembolisa-
tion, percutaneous ethanol injection and radio-frequency abla-
tion can decrease the size (and overall viability) of the tumours,
thus potentially increasing the proportion of patients qualifying
for resection and transplantation.
While the use of such downstaging therapies is straightfor-
ward when resection is the aim, in a similar way to other neo-
adjuvant treatments in the surgery of tumours that are too large
or awkwardly placed to be primarily resected the issues related
to transplantation are more complex. In the context of transplan-
tation the word ‘‘downstaging” designates not only a neo-adju-
vant treatment, but also a selection strategy to allow patients
who are initially outside accepted listing criteria to beneﬁt from
transplantation should the neo-adjuvant therapy be successful in
reducing tumour burden. The effectiveness of downstaging as a
selection strategy, at ﬁrst questioned because of methodological
bias in the studies that described it, has been recently demon-
strated by more solid prospective investigations. Several issues
however remain open, such as inclusion criteria before the strat-
egy is implemented (size/number, surrogate markers of differen-
tiation/vascular invasion such as alpha-fetoprotein), the choice of
which downstaging therapy, the end-points of treatment, and the
need and duration of a period of observation proving disease
response or stabilisation before the patient can be listed.
The present review discusses which treatments and strategies
are available for downstaging HCC on the basis of the published
literature.
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SRTR, Scientiﬁc Registry of Transplant Recipients.Curative surgical treatments for patients with hepatocellular car-
cinoma (HCC) include resection and transplantation. Resection
can be performed in patients with good liver function and local-
ised HCCs, while transplantation is favoured in selected patients
with decreased liver function and/or multiple nodules. Over the
years, the place of these therapies has been well deﬁned, but they
can only be attempted in 10–20% of patients with HCC, as in the
majority, the disease will be too advanced [1–3]. A broader use of
local HCC treatments has the potential to shrink the tumour and
allow a curative option in patients for whom tumour size or loca-
tion next to vital anatomical structures is the limiting factor.
These treatments include trans-arterial chemo-embolisation
(TACE), radio-frequency ablation (RFA), percutaneous ethanol
injection (PEI) and trans-arterial radioembolisation (TARE).
The present review article discusses the use of such local HCC
treatment prior to surgery or transplantation, and the place that
these treatments have taken in transplant candidates as a selec-
tion tool that reﬁnes the usual criteria based on number and size.Neo-adjuvant treatment vs. downstaging: a stricter deﬁnition
The word downstaging is used loosely to qualify any type of treat-
ment aiming to control tumour growth prior to surgery, with a
confusing overlap with the term neo-adjuvant treatment. In this
review we suggest restricting the use of the word downstaging
to the aim or the result of a treatment that intends to facilitate
or make possible a surgical procedure that would otherwise be
too risky or unfeasible. Neo-adjuvant treatment can be given to
patients in whom the procedure can be done primarily, with aims
that may be different from downstaging, such as to improve the
long-term results, or to limit the complications during the time
waiting for the procedure to be done. While neo-adjuvant treat-
ments often refer to the use of systemic drugs, aiming at control-
ling both the primary lesion and circulating cancer cell, it will
here be applied to local HCC therapies.
The aims of neo-adjuvant treatments and of downstaging are
different in patients who are candidate for resection or for trans-
plantation (Fig. 1). Before resection, neo-adjuvant treatment can
be given with the aim to improve the results of surgery, and
before transplantation to decrease the risk of drop-out from the
transplant waiting list, and to decrease the risks of recurrence
in the long-term. Downstaging prior to resection is performed to10 vol. 52 j 930–936
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(and dropout) from the 
waiting list.
To render possible a resection 
 that would otherwise be too 
risky or impossible
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burden is outside accepted 
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long-term outcomes among 
poor risks
(Response treatment and 
observation time used as a surrogate
markers for favourable biology)
To improve long-term 
results
(mainly for anatomical reasons)
To improve long-term
results
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treatment Downstaging
Before resection
Before transplantation
Fig. 1. Deﬁnitions of downstaging and of neo-adjuvant treatments prior to
resection or transplantation. In our opinion, the two words should not be used
as synonyms.
JOURNAL OF HEPATOLOGYrender non-operable patients operable or to simplify the surgery,
mainly for technical reasons. Finally, downstaging prior to trans-
plantation is used as a selection tool to detect patients with
low rates of recurrence among those that would be excluded
according to recognized number-size criteria. While the present
article is primarily exploring the place of downstaging, we will
also discuss neo-adjuvant options, as they help understanding
the expected beneﬁts of the various local HCC treatment
modalities.Treatment of HCC prior to resection
When an HCC can be resected primarily, a pre-surgery neo-adju-
vant treatment like TACE is usually not recommended [4]. The
main limitation is related to the time required to organize and
perform TACE, which delays resection by 2–10 weeks and pre-
vents up to 10% of patients from reaching surgery because of
tumour progression or liver failure [5,6]. In addition, resection
may be more challenging after TACE (requiring longer operative
times, often in association with signiﬁcant inﬂammatory reaction
in the hilum and around the area of parenchymal treatment),
TACE does not provide a measurable survival beneﬁt, and has
even been associated with increased mortality in two studies
[5–10]. This said, some of us do consider that one (and sometimes
two) sessions of TACE should always be attempted prior to sur-
gery, giving a chance of achieving tumour necrosis, which has
been associated with higher rates of disease-free survival [8].
Some patients with good liver function do not qualify for pri-
mary resection because of the size and/or location of one or multi-
ple HCCs, andmay be considered for downstaging. Such a strategy
has the potential to make surgery possible or easier (away from
vascular structures), and potentially with decreased risks. With
such a downstagingmanagement, a limited number of non-resect-
able patients (6–28%) can subsequently undergo surgery [11,12].Journal of Hepatology 201Although high rates of recurrence have been observed (up to 40–
85%), ﬁve-year survivals are between 25% and 60%, which is very
reasonable considering the lackof alternative andpotentially cura-
tive options in these patients [8,11–13]. The place of downstaging
as described above is relatively well accepted in the surgical com-
munity and does not require, in our opinion, further discussion
apart from the best methods to obtain it.Treatment of HCC prior to transplantation
The issues related to local HCC treatment prior to liver transplan-
tation are more complex than those related to resection. In the
setting of transplantation, these treatments will be considered
differently whether a patient is within transplant criteria at pre-
sentation or not (neo-adjuvant vs. downstaging). The treatments
will also be considered differently from a patient or a community
point of view, taking into account medical evidence-based data
and ethical considerations:
Treatment of HCCs prior to liver transplant: neo-adjuvant vs.
downstaging
Currently one third to one half of all HCC patients on the waiting
list undergo local HCC treatment prior to transplantation [14,15].
The type of treatment varies from centre to centre, but TACE is
the most frequently used, followed by RFA [14–17].
Neo-adjuvant treatments (in contrast to downstaging) are pri-
marily used to decrease the risk of drop-out from the waiting list
[16,18–23]. They may be linked to a better post-transplant
patient survival, as shown by a large UNOS-based study (78%
with treatment vs. 74.8% with surveillance alone at two years,
Risk Ratio = 0.785, p = 0.014) [17]. This data is also supported
by the observation that patients with full HCC necrosis after TACE
have better post-transplant survivals than those with partial
response [8,24]. Overall, a broader use of local neo-adjuvant
HCC treatment in patients within transplant criteria appears jus-
tiﬁed (without delaying transplantation), as the risk of signiﬁcant
side-effects of these treatments is limited, with potential lower
drop-out and higher survival rates.
A further argument in favour of local neo-adjuvant treat-
ments is that they represent the best palliative option for patients
who drop-out, avoiding the difﬁcult situation of having delayed
a proven effective treatment during the time spent on the waiting
list.
When patients have HCCs beyond the accepted transplant cri-
teria, the application of treatments aiming at downstaging
tumours appears appropriate, as this is often the only hope of
potential cure with a subsequent transplantation. In addition,
tumour response to TACE could be used as a selection tool to help
identify patients with an outcome that may be superior to that
suggested by morphological criteria alone.
This strategy was initially suggested by the group in Hopital
Paul Brousse, Paris, who retrospectively observed higher rates of
survival in TACE responders than in non-responders in an analysis
of patients with more than three nodules or nodules larger than
3 cm [8]. The wider recognition and adoption of this strategy has
been slow because of poor agreement on deﬁnition, lack of selec-
tion criteria, absence of long-term outcome data and, until
recently, the overall inability to construct prospective studies
(exceptions listed in Table 1). As an example, the original report0 vol. 52 j 930–936 931
Table 1. Selected publications on downstaging prior to transplant.*
Author Journal, year Evidence
level**
Criteria to enter
downstaging
Downstaging
treatment
(nb of patients)
Transplant
criteria
Time
stable
prior to
transplant
Downstaging
success rate
Intent-to
treat
post-HCC
treatment
survival
Post-transplant
survival
Graziadei
et al.
Liver Transplant,
2003
13 Outside Milan, no vascular
invasion, no extrahepatic
disease
TACE 50% decrease
in size
no limit 73% 31%
(at 5
years)
41%
(at 4 years
survival)
Otto et al. Liver Transplant,
2006
15 Beyond Milan, no
extra-hepatic disease
TACE (62) 30% decrease
in the
diameter
of 5 target
lesions
no limit 55% ? 74.5% (at 5
years)
Yao et al. Hepatology, 2008 16 1 lesion >5 cm and
68 cm or 2 or 3 lesions
at least 1 >3 cm but
65 cm with total tumor
diameter of 68 cm or
4 or 5 nodules all
63 cm with total tumor
diameter 68 cm
TACE, RFA and/or
resection (30)
Milan minimum 3
months
(mean: 6
months)
70% 69%
(at 4
years)
92%
(at 4 years
DFS)
Ravaioli et al. AJT, 2008 19 1 lesion >5 cm and
66 cm or 2 lesions
at least 1 >3 cm but
65 cm with total tumor
diameter of 68 cm or
4 or 5 nodules all
64 cm with total
tumor diameter 612 cm
TACE, RFA, PEI
and/or resection
(48)
Milan and
AFP
6400
ng/ml
minimum 3
months
(mean: 6
months)
90% 62%
(at 3
years)
71%
(at 3 years
DFS)
Chapman
et al.
Ann Surg, 2008 15 Beyond Milan,
no lobar major
vessel involvement
or metastasis
TACE (76) Milan usually
minimum 4
months
(mean: 6
months)
23.7% ? 100% (at
3 years)
50% (at 5 years)
Lewandowski
et al.
AJT, 2009 18 T3 TACE (43) Milan no limit 31% 19%
(at 3
years)
73% (at
1 year DFS)
TARE-Y90 (43) 58% 59%
(at 3
years)
89% (at
1 year DFS)
De Luna et al. AJT, 2009 16 Beyond Milan TACI (27) Milan no limit
(mean: 11
months)
63% 84%
(at 3
years)
78.8% (survival
at 3 years)
Jang et al. Aliment Pharmacol
Ther, 2009
11 Beyond Milan, no lobar
major vessel involvement
or metastasis
TACE (386) Milan no limit
(median: 2
months)
41.5% 25%
(at 5
years)
66.3% (at 5
years DFS)
Proposed
strategy
TTV 6250 cm3 open*** TTV6115 cm3
and AFP
6400 ng/ml
minimum 6
months
RFA: radio-frequency ablation, TACE: transarterial chemo-embolisation, TACI: transcatheter arterial chemoinfusion, TARE-Y90: transarterial radioembolization with
Yttrium-90 microspheres.
T 2: T 3: 1 nodule >5 cm or up to 3 nodules with one >3 cm
* Referenced in Medline until Oct. 25, 2009 under ‘‘liver transplant, hepatocellular carcinoma, downstaging”.
** Assessed according to the Downs and Black checklist (51).
*** Treatment is guided by tumor and patient characteristics.
Reviewfrom UCSF on downstaging included only 16 months of median
follow-up, too short to convincingly rule out the risk of HCC recur-
rence (this has been corrected in newstudies from the samegroup)
[25].
More recent reports have demonstrated that downstaging can
be successful in 24 to 90% of patients (Table 1). This wide range of
observed rates is primarily related to the use of different criteria
to include patients in downstaging protocols and different crite-
ria to subsequently decide on listing for transplantation. Some
groups consider patients for listing as soon as HCCs have
decreased in size by 30 or 50%, while others will require full
necrosis (absence of any uptake on CT) prior to doing so932 Journal of Hepatology 201[22,26–28]. In addition, some centres follow Milan transplant cri-
teria, while others use expanded ones [22,26–29].
Despite these limitations, recent prospective studies have dem-
onstrated that downstaging is a valid strategy prior to transplant
[27,28,30]: following successful downstaging, post-transplant dis-
ease-free survivals have been reported at over 70% at 3 years, and
intention-to-treat post-HCC treatment survivals between 60 and
70% at 3 years [22,27,28,30]. Such outcomes have been substan-
tially better than anticipated in a group of patients with such an
advanced cancer, in some series not just beyond Milan criteria,
but beyond UCSF criteria as well [2,31]. In addition, they appear
to compare favourably with the generally accepted minimal0 vol. 52 j 930–936
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long-term post-transplant survival of 50% at 5 years, an unreﬁned
and arbitrary target that holds consensus [32,33].
For these reasons, it appears legitimate to attempt downstag-
ing in any patient beyond transplant criteria and without distant
metastasis, even more so as downstaging treatments are identical
to palliative ones. The downside of a too liberal access to down-
staging strategies (and subsequent transplant) could be an
enhanced competition for donor livers with patients within stan-
dard transplant criteria (with or without HCC) and should be
countered by deﬁning reasonable inclusion criteria.
Which criteria should be used to include patients in a downstaging
protocol?
While any patient with HCC beyond transplant criteria, but with-
out distant metastasis, may beneﬁt from a local HCC treatment
(palliative or downstaging), we believe that only clearly selected
candidates should enter downstaging protocols. The two main
reasons for a strict attitude are: (a) the need to gather robust data
on this topic, and (b) the implicit obligation to treat all patients
on the waiting list equitably, including those with HCC or benign
disease. This even if from a patient’s point of view, transplanta-
tion may represent the best option for cure. The individual’s per-
spective that a small chance of successful transplantation is
better than the certainty of HCC progressing on palliative treat-
ment has to be balanced with the societal demand – and trans-
plant program commitment – for the responsible use of a
scarce resource.
To establish a reliable selection policy, three points have to be
taken into account
(a) deﬁned entry criteria
 size/number or total tumour volume of HCC
 biological/pathological and molecular markers(b) deﬁned end-points of successful downstaging
 radiological
i. degree of necrosis
ii. decrease in size biological: alpha-fetoprotein (AFP)
(c) deﬁned time between downstaging and listing for
transplant
Deﬁned entry criteria
The criteria to enter a downstaging program should include
patients who have well deﬁned and acceptable chances of good
outcomes after transplantation if the downstaging goal is
reached. Such a strict attitude would maintain the expansion of
transplant criteria within reasonable limits, and allow gathering
of robust and comparable data for progress. For this reason,
patients with metastasis or with large vessel thrombosis seen
on radiology should be excluded. Several groups have prospec-
tively assessed various scores (Table 1), including UNOS T3 (one
nodule >5 cm or up to three nodules with one >3 cm) or combi-
nations of size and number with up to ﬁve nodules and a total
tumour diameter of 8 or 12 cm [27,28,30]. While these scores
have not been validated externally, they appear reasonable as
they can lead to post-transplant disease-free survival rates over
70% at 3 years [27,28,30]. We would however advocate that the
UNOS T3 is too restrictive regarding tumour number, as patients
with more than three lesions (even of small size) cannot be con-Journal of Hepatology 201sidered for downstaging. Following our previous work on Total
Tumour Volume (TTV) [14,15], the group in Edmonton has
decided to include for downstaging all patients with TTV
6250 cm3. This corresponds to a single HCC of 7.8 cm in diameter
or three HCCs of 5.4 cm, but any size and number combination
can be considered as long as the cumulated tumour volume
remains within the limit. TTV does not include any number
restriction and has better expected radiological accuracy (larger
HCCs have more weight in the score and can be better deﬁned
by radiology), but downstaging results are still pending [14].
Evidence is accumulating that biological markers such as
alpha-fetoprotein (AFP) or PIVKA-II add additional predictive
accuracy if used in addition to morphological characteristics
[15,28,34,35]. We can speculate that AFP and PIVKA-II provide
a good assessment of tumour biology, including microvascular
invasion, grade and tumour aggressiveness in general. In a Scien-
tiﬁc Registry for Transplant Recipients (SRTR)-based study, we
have shown that tumour volume and AFP are independent pre-
dictors of post-transplant survival, and that morphological crite-
ria alone will miss many patients with expected poor outcomes
[15]. Even within Milan criteria, AFP values >400 ng/ml were able
to select patients at high risk of tumour recurrence.
Deﬁned end-points of successful downstaging
While it is clear that patients not responding to downstaging
should not be considered for transplantation [22,29], transplant
criteria after successful downstaging remain to be deﬁned more
precisely. We believe the most useful parameters for this are
radiological response in terms of viability and size of the
tumours, and probably biological response measured as a
decrease in AFP.
While some investigators have accepted for transplantation
patients with HCCs demonstrating partial response (decrease in
size of 30–50%), the most recent studies have considered only
patients whose tumours have demonstrated complete ablation/
no augmentation on imaging [22,26–28]. Intuitively, this attitude
makes sense as extinction of vascularisation after treatment can
be taken as a surrogate marker for a favourable biology, while
on the contrary the probabilities of a distant spread associated
with a large tumour size will likely not change if a lesion is still
partially viable.
Lesions that are fully inactive on radiology are no longer
counted as a nodule in the ﬁnal score in most studies [27,28].
As for the ﬁnal radiological end-point to deﬁne successful
downstaging, most published studies have been using the goal
of Milan criteria after treatment (with or without AFP 6400 ng/
ml) to select patients eligible for transplantation (Table 1) [27–
30,36,37]. Results have been similar to those achieved in patients
within Milan from the beginning [36].
As for biological markers, a persistently high AFP after treat-
ment should raise the suspicion of distant spread or vascular
invasion and may represent a useful marker of unsuccessful
downstaging.
Deﬁning a time between downstaging and listing for transplant
The time interval between downstaging and transplantation can
be considered an additional tool to help in the selection of HCCs
with a favourable biology. This ‘‘test of time”, will disclose rapidly
recurring lesions, vascular invasion and distant metastases. Some0 vol. 52 j 930–936 933
Review
published reports have not pre-deﬁned a minimal surveillance
time, but this was achieved in fact naturally, by a mean waiting
time of at least 6 months between activation on the waiting list
after downstaging and the date of transplantation (Table 1).
The commonest surveillance time in published reports was
3 months, and appears as the minimum required. In contrast,
centres allowing transplantation early after downstaging may
face a shift from progression on the waiting list to recurrence
in the post-transplant period, and thereby experience poor over-
all results [38].
In general, the criteria for inclusion in downstaging protocols
used to date (with an upper limit at 8 cm, or 250 cm3), while still
needing external validation within formal protocols, appear rea-
sonable, and have proven to be working. As a measure of achieve-
ment of successful downstaging we would recommend the end-
point of Milan criteria, counting fully inactive nodules as non-
existent and partially inactive nodules at their original size. We
would also suggest excluding patients with an AFP remaining
above 400 ng/ml after treatment, and a minimum observation
time of 6 months between entry into the downstaging program
and activation on the waiting list for transplantation. Additional
data forthcoming in future may validate more expanded criteria,
or a shorter surveillance period.Which local HCC downstaging treatment should be used?
The choice of a downstaging treatment should be based both on
the morphological characteristics of the HCC and on the patient
condition, balancing the risks and beneﬁts of each technique.
The efﬁciency of some treatments (including TACE and TARE) is
linked to HCC biology, with a better response in HCCs with higher
blood supply and uptake. Others are physico-mechanical treat-
ments, like RFA, where an HCC can be destroyed whether well
differentiated or not.
Radio-frequency ablation (RFA)
RFA uses radiofrequency energy for hyperthermic ablation. It can
be performed by interventional radiology or at laparoscopy. Over
time, it has replaced ethanol injection in the treatment of small
HCCs in most centres, as RFA ablation results in a higher rate of
complete necrosis (usually over 90%) and requires fewer treat-
ment sessions [39–43]. RFA is safe in terms of liver function
and can be performed even in cases of advanced liver failure
[44,45]. It is most effective for the treatment of HCCs 63 cm in
diameter (Table 2). RFA should be avoided for lesions located
close to the surface of the liver and neighbouring organs due toTable 2. Beneﬁts and limitation of local HCC treatments.
Indications
Radiofrequency ablation small HCC (usually 63 cm)
away from the liver surface
away from major vessels
Transarterial chemoembolisation any HCC size
preserved liver function (Child A-B)
uptake of contrast
Transarterial radioembolisation any HCC
preserved liver function (Child A-B)
absence of intra-hepatic shunt
uptake of contrast
934 Journal of Hepatology 201the risk of rupture of the liver capsule and seeding of malignant
cells in the peritoneal cavity. Another potential complication of
RFA (again shared with ethanol ablation or biopsy) is the seeding
of cancer along the needle tract, which has been estimated to
occur in 1–2% [16]. In addition, the use of RFA can be hampered
by the presence of ascites, which should ﬁrst be drained. In the
absence of transplantation, 5-year survivals up to 30–40% can
be expected after RFA [39,41], limited mainly by liver failure
and the development of new primaries.
Trans-arterial embolisation (TACE)
TACE is currently the most popular neo-adjuvant treatment
option for patients with HCCs [8,22,27,46]. Treatment is usually
performed using a combination of mitomycin, adriamycin or cis-
platinum mixed with lipiodol as the drug carrier and an emboli-
sation using permanent or re-absorbable occlusive particles
(gelatine). Post-procedure the patients are hospitalised for obser-
vation (usually for 24 h).
Several randomized studies have compared TACE to conserva-
tive management in HCC patients not candidate to curative
options, and when analysed together in a meta-analysis, TACE
demonstrated a signiﬁcant superiority in terms of survival [47].
TACE also allows treatment of larger tumours than RFA and
may simplify treatment of patients with multiple tumours. On
the basis of the studies quoted above, we suggest TACE may merit
consideration as the ﬁrst line neo-adjuvant option prior to resec-
tion or transplantation in the majority of patients (see Table 3).
The main risks of TACE are linked to the ischemic insults of
the embolisation. Patients with large lesions may develop a
postembolisation syndrome due to tumour necrosis, with fever
and abdominal pain. When a large area of liver parenchyma has
been embolised, patients are also exposed to the risk of liver fail-
ure, and TACE should as a rule not be attempted in patients with
decreased liver function (Child–Pugh C), except when an hyper-
selective TACE can be offered by expert hands. Finally, this proce-
dure includes a small risk of arterial injury, estimated at 2% [48].
Another limitation is linked to the poor uptake of dye by hypo-
vascular HCCs, and these lesions may be better treated with RFA.
Trans-arterial radioembolisation (TARE)
TARE is a trans-arterial procedure, which is performed by embol-
ising 20–30 lm insoluble glass microspheres impregnated with
yttrium-90 (a b emitter) (TheraSphere, MDS Nordion, Ottawa,
Canada; SIR-Spheres, Sirtex Medical Limited, Australia) [49].
The treatment induces a local necrosis of the tumour, due to
the b emission.Risks Beneﬁts
HCC seeding (1-2%)
liver rupture (small)
ok even in case of decreased liver function
only one session usually required
complete necrosis in >90% of cases
liver failure
arterial injury (2%)
ok even for large HCCs
off-target embolisation
arterial injury
ok even for large HCCs (up to 10 cm?)
ok even in case of portal vein thrombosis
more efﬁcient than TACE (to be conﬁrmed)
shorter time to response (to be conﬁrmed)
0 vol. 52 j 930–936
Table 3. Key messages.
 Downstaging = make a surgery or a transplant feasible
 Post-transplant outcomes can be similar to those of patients within Milan
 Transplant criteria should combine morphological (size/number or total tumour volume) and biological (AFP) data
 Minimum observation time = 3-6 months
JOURNAL OF HEPATOLOGYThis type of local HCC treatment has gained more interest in
recent years. It represents an interesting alternative to TACE, as
it appears to induce a more efﬁcient decrease in tumour size,
with a shorter time to response (4.2 vs. 10.9 months) [30]. In
addition, TARE can be performed in cases of portal vein thrombo-
sis, a contraindication to TACE. Finally, TARE induces a regenera-
tion of the contra-lateral liver, which may prove to be useful in
case of planned resection with a small liver remnant [50].
TARE is well tolerated in most patients leading to a discharge
within 2–6 h (without inpatient surveillance like TACE). The most
common side-effects include fatigue and ﬂu-like symptoms [30].
Several complications of TARE are similar to those of TACE,
including the risk of arterial injury [51]. The presence of excessive
intrahepatic shunting should be excluded by 99Tc-macroaggre-
gated albumin scanning and mesenteric angiogram to minimize
the risk of nontarget embolisation, especially radiation injury to
the lungs [30]. While TARE has several advantages over TACE,
its place remains to be fully deﬁned (together with its cost-efﬁ-
ciency) [30].
Altogether, the choice of a local HCC treatment should be
guided by the tumour and patient characteristics, as well as the
local expertise. In consideration of the relative advantages and
risks of ablative and trans-arterial approaches, we would suggest
primary application of RFA for more centrally placed tumours
when <3 cm diameter and in candidates with poor liver function
who may not tolerate trans-arterial therapies well. TACE or TARE
should receive primary consideration in candidates with satisfac-
tory liver function when tumours are above optimal size for RFA
(>3 cm), when multiple tumours are present or when tumours
are in a subcapsular position or adjacent to major vessels or bile
ducts. Incomplete control should lead to re-evaluation and con-
sideration of the alternative approaches.
Final considerations
While further validations to reﬁne the application of downstag-
ing strategies are required, most of them appear reasonable,
and can be used advantageously in patients with primarily unre-
sectable tumours before partial hepatectomy, or to identify
patients with a high likelihood of a good outcome despite being
outside current transplantation criteria. Current evidence sug-
gests that patients with solitary HCCs up to 8 cm in diameter
and with up to ﬁve tumours (all 64 cm with total tumour diam-
eter 612 cm) can be considered for downstaging. We would
favour combining these cut-offs within the Total Tumour Volume
score (250 cm3), or with the up to seven criteria recently pub-
lished by the Metroticket collaborative study group [15,52].
Patients who reach traditional Milan criteria (inactive tumours
counting as zero), with no contraindication to transplantation
appearing during a waiting time of at least 3 months (ideally
6 months) have a more favourable biology, as shown by a low
recurrence rate. These criteria may be further reﬁned by adding
AFP as a selection marker, and should be conﬁrmed in further
prospective investigations that are organised in the present col-
laborative spirit.Journal of Hepatology 201Conﬂicts of interest
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